An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

Inclusion Criteria:

- Diagnosis of congenital hemophilia A of any severity and documented history of
high-titer inhibitor (that is [i.e.], greater than or equal to [>/=] 5 Bethesda Units)

- History of treatment with episodic or prophylactic bypassing agents for at least the
last 24 weeks

- >/=6 (if on an episodic bypassing agent regimen) or >/=2 (if on a prophylactic
bypassing agent regimen) bleeds within 24 weeks prior to screening

- Currently using recombinant activated factor VII (rFVIIa) or are willing to switch to
rFVIIa as primary bypassing agent for the treatment of breakthrough bleeds

- Adequate hematologic function, defined as platelet count >/= 100,000 per microliters
(mcL) and hemoglobin >/=8 grams per deciliter (g/dL) at screening

- Adequate hepatic and renal function

Exclusion Criteria:

- Inherited or acquired bleeding disorder other than hemophilia A

- Ongoing (or plan to receive during the study) immune tolerance induction (ITI) therapy
or prophylaxis with FVIII with the exception of participants who have received a
treatment regimen of FVIII prophylaxis with concurrent bypassing agent prophylaxis

- Treatment for thromboembolic disease within 12 months before Day 1 (with the exception
of previous catheter-associated thrombosis for which antithrombotic treatment is not
currently ongoing) or current signs of thromboembolic disease

- Other conditions (example [e.g.], certain autoimmune diseases) that may increase the
risk of bleeding or thrombosis

- High risk for thrombotic microangiopathy (TMA), in the investigator's judgment

- History of clinically significant hypersensitivity associated with monoclonal antibody
therapies or components of the emicizumab injection

- Use of systemic immunomodulators (e.g., interferon or rituximab) at enrollment or
planned use during the study, with the exception of antiretroviral therapy

- Treatment with any of the following: An investigational drug to treat or reduce the
risk of hemophilic bleeds within 5 half-lives of last drug administration before Day
1; A non-hemophilia-related investigational drug within the last 30 days or 5
half-lives before Day 1, whichever is longer; An investigational drug concurrently

- Any serious medical condition, treatment, or abnormality in clinical laboratory tests
that, in the investigator's judgment, precludes the participant's safe participation
in the study